You are here

Treatment with thalidomide or lenalidomide for a malignant disease

Document

Deep vein thrombosis - Treatment with thalidomide or lenalidomide for a malignant disease Factor

Last reviewed for CCPS 22 December 2008.

Preliminary questions [40405]

40410 there is some evidence that treatment with thalidomide or lenalidomide for a malignant disease may be a factor in the development of the condition under consideration.

40419 the veteran has been treated with thalidomide or lenalidomide for a malignant disease at some time.

40420the malignant disease for which the veteran was treated with thalidomide or lenalidomide is an illness or injury which is identifiable.

40421 for the identified illness or injury, a malignant disease, the veteran was treated with thalidomide or lenalidomide within the 90 days before the clinical onset of the condition under consideration.

40422the veteran has established the causal connection between being treated with thalidomide or lenalidomide for a malignant disease and VEA service for the clinical onset of deep vein thrombosis.

40423the veteran has established the causal connection between being treated with thalidomide or lenalidomide for a malignant disease and operational service for the clinical onset of deep vein thrombosis.

or

40424the veteran has established the causal connection between being treated with thalidomide or lenalidomide for a malignant disease and eligible service for the clinical onset of deep vein thrombosis.

Clinical onset and operational service [40423]

40425the identified illness or injury, a malignant disease that was treated with thalidomide or lenalidomide, is causally related to operational service.

Clinical onset and eligible service [40424]

40426the identified illness or injury, a malignant disease that was treated with thalidomide or lenalidomide, is causally related to eligible service.